Featured Research

from universities, journals, and other organizations

A Debate On Smokeless Tobacco

Date:
July 4, 2007
Source:
Public Library of Science
Summary:
In a debate in this week's PLoS Medicine, public health researchers discuss whether or not the public should be informed that using oral, smokeless tobacco (Swedish snus) is less hazardous to health than smoking tobacco.

Should the health community promote smokeless tobacco (snus) as a harm reduction measure?

In a debate in this week's PLoS Medicine, public health researchers discuss whether or not the public should be informed that using oral, smokeless tobacco (Swedish snus) is less hazardous to health than smoking tobacco.

Arguing the case for providing such information, Carol Gartner and Wayne Hall (University of Queensland, Australia) point to the Swedish experience. Snus seems to be widely used as an alternative to cigarettes in Sweden, contributing to the low overall prevalence of smoking and smoking-related disease. "On the Swedish experience," say Gartner and Hall, "there is a strong prima facie case on public health and ethical grounds for recommending snus to inveterate smokers who want to reduce their health risks and for considering public policies, such as lower taxes for snus and public information campaigns, to promote its use by smokers."

However, Simon Chapman and Becky Freedman (University of Sydney, Australia) argue that Sweden's experience is likely to be specific to that culture and not transferable to other settings, and that if tobacco companies are allowed to market snus they will undoubtedly use the opportunity to promote tobacco as well. "Snus enthusiasts in the public health community," say Chapman and Freedman, "focus on snus' potential to take people away from smoking. However transnational tobacco companies are already marketing snus using slogans that mention smoking, such as: 'When you can't smoke, snus.'"

Citation: Gartner CE, Hall WD, Chapman S, Freeman B (2007) Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med 4(7): e185


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Cite This Page:

Public Library of Science. "A Debate On Smokeless Tobacco." ScienceDaily. ScienceDaily, 4 July 2007. <www.sciencedaily.com/releases/2007/07/070703172903.htm>.
Public Library of Science. (2007, July 4). A Debate On Smokeless Tobacco. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/07/070703172903.htm
Public Library of Science. "A Debate On Smokeless Tobacco." ScienceDaily. www.sciencedaily.com/releases/2007/07/070703172903.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins